**DRUG UTILIZATION REVIEW BOARD MEETING**
**April 21, 2010**
**205 JEFFERSON STREET**
**JEFFERSON CITY, MO 65101**

**Board Members Present**

John Newcomer, MD, Chairman
David Campbell, M.D
Charlene Heyde, RPh
Peggy Wanner-Barjenbruch, MD
Susan Abdel-Rahman, PharmD
Randy Becker, PharmD
Sandra Bollinger, PharmD
Glenn Talboy, MD (**Pending Confirmation)**

**Board Members Absent:**

Joy Gronstedt, DO
Jennifer Passanise, FNP
Joseph Yasso, DO
Sharad Parikh, M.D.
Stacy Mangum, PharmD

**MO HealthNet Division Staff Present:**

George L. Oestreich, Deputy Division Director
Rhonda Driver, RPh, Director Pharmacy Program
Jenna Twehus, RN
Mary Heet, RN
Tisha McGowan, Unit Supervisor, DUR Coordinator
Andrew Haslag, Fiscal Manager
Beth McQuaide, Special Assistant
Angela Wilson, Unit Supervisor
Kim Morgan, Correspondence and Information Specialist
Jackie Hickman, Unit Supervisor

**Contractors in Attendance:**

Rick Pope, PharmD, First Health Services
Tom Beetem, RPh, Infocrossing
Jennifer Kemp-Cornelius, PhamD, ACS
Mark Roaseau, MD, PharmD, ACS
Sophie Backes, ACS
Geri Roling, Infocrossing
Annette Walther, Infocrossing

**Others Attending:**

Jeff Himmelberg, GSK
Kelli Frank, Eurand
Pam Sardo, Abbott
Jerry McCurren, Otsuku
Scott Edelhauser, Alcon
Dan Doucette, Purdue
Eric Blake, Schering Plough
Julie Mendoza, Eurand
D. King, Amgen
Lon Lowry, Novartis
Patty Minear, Eli Lilly
Carol Curtis, Astra Zeneca
Nick Boyer, Astra Zeneca
Eric Gardner, Pfizer
J. Graham, Centocor
Scot ?, Pfizer
Chet Steckler, Purdue
Nancy Forlenza, Eurand
John Harris, Abbott
Grant Cale, BMS
Christopher White, StLCop Student
Ismar Karendzoc, StLCop Student

*Some names illegible. Sign in sheet on file for review.

| | |
|---|---|
| **Welcome, Introductions and Opening Remarks** | Chairman, John Newcomer, MD called the meeting to order at 10:00 a.m. A quorum was established. Introductions were made and new DUR Member, pending confirmation, Glenn Talboy, MD was welcomed. Members awaiting information regarding their application to the Governor's office were asked to check with Rhonda Driver, RPh, Director of Pharmacy following the meeting to update on any communications regarding reappointment. Dr. Newcomer announced that agenda items were being rearranged as George Oestreich, PharmD, Deputy Division Director would be joining the meeting late. A folder of correspondence received and responded to during the quarter, pertaining to the agenda topics, was shared with the Board. A copy of this correspondence is available to Board members upon request. |
| **Minutes Approval** | Minutes of the January 2010 meeting were reviewed and approved as submitted. |
| **ACS Healthcare Update** | Jennifer Kemp-Cornelius, PharmD followed up on previous discussions including antipsychotic coordination of care interventions. Dr. Kemp-Cornelius summarized various potential flags. These flags may be changed at the request of the Board. Ms. Driver provided background into the previous intervention review process through the Regional DUR Committee, which was a paper intensive process that has been retired. The Division plans to allow the Board access to the CyberFormance™ tool for specific populations in order to provide input into these interventions. A demonstration of the tool, with specific patient information, will be scheduled for a later meeting during executive session. Extensive discussion ensued in support of these disease management interventions especially since the legislation surrounding psychotropic medications was killed due to heavy lobbying. Lon Lowry, Novartis Pharmaceuticals and PhMARA Chairman addressed the group in response to these comments. He summarized the process for this legislation including the early discussions for a preferred drug list for psychotropic products, as well as the formation of a new committee to review recommendations, which PhMARA was opposed to. He stated the organization does not believe this class is appropriate for supplemental rebate management. He stated the position of the PhMARA Task Force is and always has been that the State of Missouri has the authority to address outliers in this drug class through the DUR statute and clinical edits. Dr. Kemp-Cornelius also followed up on a question providing the number of dispensed tramadol claims while a patient was also on an SSRI. A handout on serotonin syndrome was provided for the members' information. A follow up to a question from the Board regarding Zyvox concurrent use with an SSRI was also provided. |
| **Pharmacy Program/Budget Update** | Dr. Oestreich stated the recommendation for changes to the bill surrounding psychotropic medications has been withdrawn and removed from the Governor's recommendations. MHD is particularly concerned with children and the usage of these medications and will work with the Board to develop oversights and to identify outliers and inappropriate prescribing practices to address quality of health concerns as well as monitor for inappropriate expenditures at this difficult financial time for the state. Dr. Oestreich summarized the appropriations process starting in October and the state of the state which is the kick off for the budget process. He indicated his latest understanding of the smoking cessation issue was an amendment to the budget bill had been added by Senator Schafer for services and was headed to conference discussion this |

| | |
|---|---|
| | week and will end up, if passed, somewhere between the House, the originator of all spending bills, version of zero and the Senate version of $8 million dollars allocated to the program. An overview of the current status of the MO HITECH project straw-model, just released today, was provided. Dr. Oestreich noted that Department of Social Services Director, Ron Levy, is serving as the Health Information Coordinator for the state. This is a requirement of ARRA for funding to create Health Information Exchanges in all states. Dr. Oestreich is serving as the Project Director for MO HITECH. Missouri is the recipient of approximately $14 million for the planning and development of an exchange. Dr. Oestreich discussed the Request for Information out to learn of existing assets within the state and the funding of a Regional Extension Center to the University of Missouri to support the implementation of electronic health records in provider offices. The activities of the stakeholders of approximately 500 engaged participants working in six workgroups and an advisory board were summarized. A Web page for the MO HITECH initiative is available for anyone who is interested in further detail and will include the slides presented today. Medicaid is running a parallel planning process and has received funding to support the development of a planning advance planning document (PAPD). The remainder of the presentation was opened for questions.<br><br>Ms. Driver responded to questions regarding healthcare reform highlighting expected changes expected to impact the state.<br><br>A more in depth MO HealthNet background presentation, including budget, IT support, and the claims adjudication process will be planned for the next meeting to assist new members with the discussions.<br><br>Carol Curtis announced the retirement of Lon Lowry and thanked him for his many years of dedicated service to the pharmaceutical industry. |
| **Review of Prior Authorization Meeting:** | Copies of the agenda and draft minutes, including public hearing, from the March 2010 *Drug Prior Authorization Meeting* were included in the members' meeting packet. |
| **Implementation Schedule** | An updated copy of the *Proposed Implementation Schedule for Edits,* including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had been updated with all edits approved at the last quarter's meetings. This schedule may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf |
| **Megestrol Acetate** | • **Discussion –**Ms. Driver reviewed the criteria document provided in the meeting packet and to all attendees. She noted this review was at the request of the manufacture following the new drug review of Megace ES. She reminded that during the discussion of the product, at the December 2009 Drug Prior Authorization Committee meeting, a request for a utilization review had been made. Ms. Driver reported MHD recommends the addition of Megace ES to the existing megestrol acetate clinical edit, as data shows appropriate utilization of the product. She noted denial criteria had been amended to edit for appropriate dosing of the products.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This recommendation |

| | |
|---|---|
| | was included in the block vote. (See Roll Call Vote) |
| **New Drug Review** | • **Discussion -** Drug monographs were available for review at http://www.heritage-info.com/mocaidrx for all new products reviewed this quarter (Identified by First Data Bank in October, November and December). A listing of products recommended for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout (see meeting packet) to all attending. Ms. Driver reviewed MHD recommendations.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. New Drug recommendations were included in this block vote. (See Roll Call Vote) |
| **Preferred Drug List (PDL)** | Products and classes under review this quarter have existing contracts through June 30, 2010. Annual review recommendations approved by the Board will be scheduled for implementation in July 2010. |
| **Antiemetics-Oral** | • **Discussion –** Ms. Driver reviewed the criteria document included in the meeting packet. Preferred and non preferred products were reviewed as well as approval and denial criteria. No change from the current edit was recommended.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Beta-Adrenergic Long Acting** | • **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products and approval/denial criteria. No change was recommended for this class.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Beta Adrenergic-Nebulized** | • **Discussion –** Ms. Driver reviewed the criteria document. The addition of Levalbuterol Solution to non preferred status was the only change to the existing edit.<br>• **Decision -** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted as presented and added to the block vote.<br>(See Roll Call Votes) |
| **Beta Adrenergic-Short Acting** | • **Discussion –**Ms. Driver reviewed the criteria document. No changes were recommended<br>• **Decision -** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **COPD Anticholinergics** | • **Discussion –**Ms. Driver reviewed the criteria document. No change was recommended.<br>• **Decision -** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |

| | |
|---|---|
| **Hematopoietic Agents** | • **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products and approval/denial criteria. Ms. Driver noted the movement of Procrit® for preferred status making all products preferred. .<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Inhaled Corticosteroids** | • **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products and approval/denial criteria. No change was recommended from the current edit.<br>• **Decision –** This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Insulins** | • **Discussion –** Ms. Driver reviewed the criteria. No change was recommended for this class.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Long Acting Insulins** | • **Discussion –** Ms. Driver reviewed the criteria document. No change was recommended and all products in this class remain preferred.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Rapid Acting Insulins** | • **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products. No change to the current edit was recommended.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Insulin Mix** | • **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products. No change to the current edit was recommended.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Ophthalmic NSAIDS** | • **Discussion –** Ms. Driver reviewed the criteria document noting the movement of two products (Acular Drops and Acular LS Drops) and the addition of a new product (Acuvail® Dropperette) to non preferred status. Ketroalac Drops and Ketorolac LS Drops were new additions to preferred status.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion.This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Seditive Hypnotics** | • **Discussion –** Ms. Driver summarized the criteria document noting the addition of a new product (Edular®) and the movement of Rozerem to non preferred status. Ms. Driver stated the decision to move Rozerem was following a year of utilization data which did not warrant preferred status. Approval criteria remains in |

| | |
|---|---|
| | place and allows transparent approval after trial on one preferred agent for patients with diagnostic history of substance abuse.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Statins** | • **Discussion –** Ms. Driver reviewed the criteria document noting no status change for the products to the existing edit. Approval criteria surrounding secondary prevention targets and transparent access to high potency stains with specific diagnosis was incorporated into the edit<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted into the block vote.( See Roll Call Votes) |
| **Triglyceride Lowrig Agents** | • **Discussion –** Ms. Driver reviewed the criteria document noting significant changes to the current edit. Lipofen® and Fenofibrate were moved to the non preferred side of the edit. New products Fibricor® and Fenofibric were also additions to non preferred status.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Urinary Tract Antispasmodics** | • **Discussion –** Ms. Driver reviewed the criteria document noting the movement of Oxytrol® from preferred to non preferred status..<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Growth Hormones** | • **Discussion –** Ms. Driver reviewed the criteria document. One product (Omnitrope®) was being recommended for movement from preferred status to the non preferred side of the edit. Members were reminded that clinical criteria remain in place for this class.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Androgen Hormone Inhibitors** | • **Discussion –** Ms. Driver reviewed the criteria document noting no change to the current edit.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Non-Ergot Dopmine Receptor Agonists** | • **Discussion –** Ms. Driver reviewed the criteria document noting the addition of new product Pramipexole to non preferred status and the removal of Neupro® from the class.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |

| | |
|---|---|
| **Low Molecular Weight Heprins** | • **Discussion –** Ms. Driver reviewed the criteria document noting no change to the current edit.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Skeletal Muscle Relaxants** | • **Discussion –** Ms. Driver reviewed the criteria document noting the clinical criteria including duration of therapy limits. The recommendation to move Carisoprodol and Carisoprodol Compound to non preferred status following extensive discussion at the Drug Prior Authorization Committee meeting of the results of a focus group study completed by the Department of Mental Health, that included utilization of Soma was incorporated into the edit.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Benzoyl Persoxide/Clindamycin Topical Agents** | • **Discussion –** Ms. Driver reviewed the criteria document. The movement of Duac CS® and the addition of new product Acaya® to non preferred status were noted.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Platelet Inhibitor Agents** | • **Discussion –** Ms. Driver reviewed the criteria document noting the addition of a new product Effient® to non preferred status.<br>• **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes) |
| **Preferred Drug List Discussion/Therapeutic Classes** | A handout of therapeutic categories for review and inclusion in the PDL during the next quarter was included in the meeting packet and to all meeting attendees. This listing will be posted to the Division's Web page at http://www.dss.mo.gov.mhd |
| **Program Statistics:** | |
| **Top 25 Drugs by Cost** | Top 25 drug lists for the 1st, 2nd, 3rd and 4thquarters of 2009 were provided for the Boards' information. These reports were provided by number of claims and amount paid format. Copies were available to all attendees. |
| **Clinical Edit Summary Report** | An overview report of the clinical edit and prior authorization request transaction counts for the month of March 2010 was provided for all attending. The report detailed total transaction counts as well has information on the outcome (approval or denial) of the request. |
| **Call Center Statistics** | A handout illustrating pharmacy help desk call center activity was provided for all attending. Statistics for February and March 2010 were included. Also included for the Boards' information was a CyberAccess™ Report. This report detailed statistics for CyberAccess™ usage from April 2006 through March 2010 and showed how usage has grown overtime and as edits are implemented. |
| **Adjourn** | The DUR Board went into Executive Session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further |

| | |
|---|---|
| | business, actions or motions. (See attached roll call vote) The next meeting is scheduled for July 21, 2010 |

**Roll Call Votes – April 21, 2010**

| Member | Block Vote for all Recommendations | Closed Session | *Adjourn* |
|---|---|---|---|
| Susan Abdel-Rahman | **Motion** | Yeah | Yeah |
| Randy Beckner | ** see below* | **Motion** | *Yeah* |
| Sandra Bollinger | Yeah | **Second** | Yeah |
| Jennifer Passanise | Absent | *Absent* | *Absent* |
| David Campbell | Yeah | Yeah | **Second** |
| Joy S. Gronstedt | Absent | Absent | Absent |
| Stacy Mangum | Absent | *Absent* | *Absent* |
| John Newcomer | Yeah | Yeah | Yeah |
| Sharad Parikh | Absent | Absent | Absent |
| Charlene Heyde | Yeah | Yeah | **Motion** |
| Peggy Wanner-Barjenbruch | **Second** | Yeah | Yeah |
| Joseph M. Yasso | Absent | *Absent* | *Absent* |

***Dr. Beckerner abstained from the vote on the following PDL Classes: Oral Antiemetic, Beta Adrenergic Agents Long Acting, Inhaled Corticosteroids, Triglyceride Lowering Agents, Urinary Tract Antispasmodics, Androgen Hormone Inhibitors, Non-Ergot Dopamine Receptor Agonists, Low Molecular Weight Heprins. His vote is recorded as Yeah for all other classes.**

**EXECUTIVE SESSION**
April21, 20109

**Board Members Present**

John Newcomer, MD, Chairman
David Campbell, M.D
Charlene Heyde, RPh
Peggy Wanner-Barjenbruch, MD
Susan Abdel-Rahman, PharmD
Randy Becker, PharmD
Sandra Bollinger, PharmD
Glenn Talboy, MD (**Pending Confirmation)**

**Board Members Absent:**

Joy Gronstedt, DO
Jennifer Passanise, FNP
Joseph Yasso, DO
Sharad Parikh, M.D.
Stacy Mangum, PharmD

**MO HealthNet Division Staff Present:**

George L. Oestreich, Deputy Division Director
Rhonda Driver, RPh, Director Pharmacy Program
Jenna Twehus, RN
Mary Heet, RN
Tisha McGowan, Unit Supervisor, DUR Coordinator
Andrew Haslag, Fiscal Manager
Beth McQuaide, Special Assistant
Angela Wilson, Unit Supervisor
Kim Morgan, Correspondence and Information Specialist
Jackie Hickman, Unit Supervisor

**Contractors in Attendance:**

Rick Pope, PharmD, First Health Services
Jennifer Kemp-Cornelius, PhamD, ACS
Mark Roaseau, MD, PharmD, ACS
Sophie Backes, ACS

| | |
|---|---|
| Minutes Review | Minutes of the January Executive Session were approved as submitted |
| Case Reviews | In the interest of time and due to the large open session agenda no case reviews were presented. |
| Adjourn | Executive session adjourned. (See roll call vote) |